Consistent with prior rosnilimab studies, a favorable safety and tolerability profile was observed, even at a 33% higher cumulative dose through 6 months in the 800mg Q2W cohort relative to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback